Modeling Principle

The Beagle Fever Model is a standardized translational large-animal model widely recognized in research on antipyretic drug development, thermoregulatory mechanisms, systemic inflammatory response, pathophysiology of early sepsis, and central-peripheral thermoregulatory network. Lipopolysaccharide (LPS) administered intravenously or intraperitoneally is predominantly adopted to establish endotoxin-induced pyrexia. Zymosan or bacterial suspension can be alternatively used to construct exogenous pyrogen-mediated fever phenotypes. Pyrogens stimulate the monocyte-macrophage system to robustly release endogenous pyrogens including IL-1β, IL-6 and TNF-α. These mediators cross the blood-brain barrier and target the preoptic area of hypothalamic thermoregulatory center, raise the body temperature set-point, and induce stable and reproducible biphasic fever response, faithfully recapitulating the pathological process of infection-evoked fever in clinic.

Compared with rodent models, Beagle dogs exhibit human-like baseline temperature range, circadian rhythm of body temperature, hypothalamic thermoregulatory pathways, sensitivity to pyrogenic mediators, and cardiovascular-metabolic compensation patterns. Stable venous access is easy to establish in Beagles; continuous non-invasive core temperature monitoring and repeated blood sampling allow dynamic tracking of inflammatory cytokine fluctuations. This model is suitable for pharmacodynamic and safety evaluation of long-acting antipyretic agents, targeted anti-inflammatory drugs and central thermoregulatory interventions. Standardized dosage, ambient temperature control and temperature monitoring protocols effectively reduce intra-group data dispersion, meeting experimental specifications of high-impact pharmacological SCI journals, National Natural Science Foundation projects, and postgraduate proposals and dissertations. It is extensively applied in preclinical efficacy assessment of novel antipyretic drugs, immune-metabolic mechanisms underlying fever, and early intervention against sepsis.

Modeling Success Criteria

Quantitative Functional Criteria

Compared with blank control group, animals in model group exhibit typical monophasic or biphasic fever response. Core temperature rises ≥1.0 ℃ above baseline with distinct fever peak and sustained fever duration ≥4 h. Serum IL-1β, IL-6 and TNF-α levels are significantly higher than blank control. No spontaneous persistent temperature abnormality or massive animal death from shock occurs. Good intra-group repeatability of temperature rising timeline and peak amplitude enables stable discrimination of drug effects on lowering fever peak, shortening fever duration and accelerating temperature recovery, confirming successful establishment of fever model.

Molecular and Pathological Gold-Standard Indexes

Pro-inflammatory cytokines in serum are markedly up-regulated during fever peak; pyrexia-related signaling pathways are activated in hypothalamic preoptic area; peripheral circulating monocytes are activated. No extensive non-specific organ injury or severe endotoxin shock is observed. Only controllable inflammatory fever phenotype appears, avoiding confusion between drug antipyretic effect and simple anti-shock protection, ensuring model specificity.

Academic Evidence for Model Validity

Core evaluation evidence for standardized Beagle LPS fever model: exogenous pyrogen triggers release of endogenous pyrogens, elevates hypothalamic temperature set-point and induces temporally stable inflammatory fever, completely simulating the pathophysiological cascade of fever in early clinical infection. The model can simultaneously reflect peripheral anti-inflammatory efficacy and central thermoregulatory intervention effects, serving as the recognized reliability standard of large-animal models for translational preclinical research of antipyretic agents.

Model Advantages

The Beagle Fever Model is a mainstream large-animal model in antipyretic pharmacology and translational inflammatory immunology. Thermoregulatory pathways and response characteristics to pyrogenic mediators are highly homologous to humans. Continuous non-invasive core temperature monitoring and multi-time-point serial blood sampling are achievable. Intravenous administration route mimics clinical delivery patterns. Stable and reproducible fever curves support quantitative evaluation of antipyretic time-effect and dose-effect relationship of test articles. Experimental data integrate functional, kinetic and inflammatory molecular indicators to form complete evidence chain with high translational value. Research conclusions are readily accepted by SCI journals in pharmacology and pharmaceutics, suitable for NSFC application, research proposals and postgraduate dissertations.

Research Applications

The Beagle Fever Model is applied to systematically elucidate molecular pathways underlying endogenous pyrogen-mediated elevation of hypothalamic temperature set-point; quantitatively evaluate in vivo antipyretic activity, time-effect characteristics and safe dose window of chemical drugs, natural products and biological agents; investigate regulatory effects of antipyretic drugs on systemic inflammatory cytokine storm; perform preclinical pharmacodynamic assessment of novel intravenous formulations, long-acting sustained-release preparations and central targeted anti-inflammatory agents; explore thermoregulatory compensation under stress, anesthesia and comorbid conditions. It provides large-animal translational data complying with pharmacological guidelines for new antipyretic drug declaration, widely supporting basic mechanistic research, new drug development, funding projects, dissertations and SCI manuscript preparation.

Beagle fever model, LPS-induced pyrexia, thermoregulation, inflammatory fever, systemic inflammatory response syndrome, antipyretic pharmacodynamics, central thermoregulation, translational large animal fever model